based on the potential toxicity of medium-chain fatty acid metabolites and the beneficial responses of patients with other inborn errors of metabolism and secondary carnitine deficiency , oral carnitine has been proposed as treatment for children with medium-chain acyl-coa dehydrogenase deficiency .
C0025521
inborn errors of metabolism
C0342788
carnitine deficiency